Home page4DX • ASX
add
4DMedical Ltd
Chiusura precedente
0,27 $
Intervallo giornaliero
0,27 $ - 0,30 $
Intervallo annuale
0,23 $ - 0,72 $
Cap di mercato
128,37 Mln AUD
Volume medio
988.922,00
Rapporto P/E
-
Dividendo/Prezzo
-
Borsa valori principale
ASX
Notizie del mercato finanziario
Dati finanziari
Conto economico
Entrate
Utile netto
(AUD) | dic 2024info | Variazione Y/Y |
---|---|---|
Entrate | 1,45 Mln | 265,33% |
Spese di gestione | 13,10 Mln | 7,86% |
Utile netto | -9,58 Mln | -22,82% |
Margine di profitto netto | -662,04 | 66,38% |
Utili per azione | — | — |
EBITDA | -11,23 Mln | -1,87% |
Aliquota fiscale effettiva | -0,04% | — |
Stato patrimoniale
Totale attivo
Totale passivo
(AUD) | dic 2024info | Variazione Y/Y |
---|---|---|
Investimenti cash/breve termine | 15,95 Mln | -66,68% |
Totale attivo | 102,01 Mln | -29,03% |
Totale passivo | 42,15 Mln | -19,87% |
Patrimonio netto totale | 59,86 Mln | — |
Azioni in circolazione | 413,32 Mln | — |
Prezzo/valore contabile | 1,93 | — |
Redditività dell'attivo | -28,80% | — |
Rendimento sul capitale | -45,42% | — |
Flusso di cassa
Flusso di cassa netto
(AUD) | dic 2024info | Variazione Y/Y |
---|---|---|
Utile netto | -9,58 Mln | -22,82% |
Liquidità di esercizio | -7,07 Mln | 4,01% |
Contanti da investimenti | -422.550,00 | 97,85% |
Contanti da finanziamenti | 170.006,00 | -98,95% |
Flusso di cassa netto | -7,33 Mln | 32,46% |
Flusso di cassa libero | -6,17 Mln | 4,49% |
Informazioni
4DMedical is a medical technology company, based in Australia and the United States.
4DMedical created X-ray Velocimetry Lung Ventilation Analysis Software based on the company's proprietary XV Technology. XV Technology uses patented algorithms adapted from advanced aerodynamics research to process and enhance X-ray and Computed Tomography images. Airflow is measured throughout all regions of the lung, across all phases of the breath—providing clinicians with quantitative lung ventilation data in a report.
4DMedical has commercialized its XV Technology via a Software as a Service model, where patients are scanned using existing imaging equipment and analyzed by 4DMedical remotely. Airflow is measured throughout all regions of the lung, across all phases of the breath, delivering the capability to quantify regional lung function throughout the respiratory cycle, at every location within the lung. The lung function data is provided to clinicians and patients in a report that includes color-coded lung images. This approach enables the detection of subtle functional losses before lung structure is irreversibly effected by the disease. Wikipedia
Fondazione
2013
Sito web
Dipendenti
145